Patients will receive RCD or PCD combination as induction treatment followed by rituximab or velcade maintenance therapy, as the investigators try to compare the, very good partial remission (VGPR) rate, complete remission (CR) rates, Overall remission rate (MR+CR + VGPR + partial remission (PR) rate), major reaction rate (MRR, PR+VGPR+CR) at the end of the research.
This is an open-label, single-centre, randomised study, looking at a series of 40 patients up to the age of 75 with newly diagnosed Waldenstrom's macroglobulinemia (WM) not previously treated. Patients will receive RCD or PCD combination as induction treatment followed by rituximab or velcade maintenance therapy, as the investigators try to compare the, very good partial remission (VGPR) rate, complete remission (CR) rates, Overall remission rate (MR+CR + VGPR + partial remission (PR) rate), major reaction rate (MRR, PR+VGPR+CR) at the end of the research.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
40
rituximab:375mg/m2 ,Dexamethasone 20mg q12h,cyclophosphamide 750mg
Velcade:1.3mg/m2,Dexamethasone 10mg q12h,cyclophosphamide 750mg
First Affiliated Hospital, Soochow University
Suzhou, Jiangsu, China
RECRUITINGInvestigators try to compare the very good partial remission (VGPR) rate at the end of the research.
Time frame: 2 years
Investigators try to compare the complete remission (CR) rates at the end of the research.
Time frame: 2 years
Investigators try to compare Overall remission rate (MR+CR + VGPR + partial remission (PR) rate) at the end of the research.
Time frame: 2 years
Investigators try to compare major reaction rate (MRR, PR+VGPR+CR) at the end of the research.
Time frame: 2 yeas
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.